AngioDynamics (NASDAQ:ANGO) issued an update on its FY20 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.25-0.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.26. The company issued revenue guidance of $280-286 million, compared to the consensus revenue estimate of $280.90 million.AngioDynamics also updated its FY 2020 guidance to $0.25-0.30 EPS.
NASDAQ ANGO traded up $0.56 on Wednesday, hitting $21.06. The company’s stock had a trading volume of 510,100 shares, compared to its average volume of 218,894. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.70 and a current ratio of 2.68. AngioDynamics has a 1-year low of $18.11 and a 1-year high of $25.48. The stock’s 50-day simple moving average is $19.52. The company has a market capitalization of $757.80 million, a price-to-earnings ratio of 28.46 and a beta of 0.69.
AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.25. AngioDynamics had a net margin of 1.30% and a return on equity of 5.41%. The business had revenue of $96.30 million for the quarter, compared to analyst estimates of $92.34 million. During the same period in the prior year, the firm earned $0.20 earnings per share. AngioDynamics’s revenue was up 9.1% on a year-over-year basis. As a group, research analysts expect that AngioDynamics will post 0.83 earnings per share for the current fiscal year.
Several equities analysts have recently weighed in on ANGO shares. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. TheStreet lowered shares of WCF Bancorp from a c rating to a d+ rating in a report on Thursday, April 18th. Zacks Investment Research raised shares of Investar from a hold rating to a buy rating and set a $27.00 target price on the stock in a research note on Tuesday, June 4th. Finally, BidaskClub raised shares of Zebra Technologies from a hold rating to a buy rating in a research note on Saturday. Four research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. AngioDynamics currently has a consensus rating of Hold and a consensus price target of $21.50.
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.
Read More: What is a balanced fund?
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.